RESUMEN
Objectives: Growth hormone (GH) therapy's capacity to increase height velocity and height at the end of the study in children with idiopathic short stature (ISS) is controversial. We aimed to investigate the height standard deviation score (SDS) and height velocity of patients with ISS in Korea who received GH treatment. Methods: We retrospectively reviewed and performed linear mixed model and survival analyses on data from 12 tertiary hospitals in Korea, including subjects diagnosed with ISS from January 2009 to September 2019, treated with GH therapy for more than 6 months, and who were at a pre-pubertal state at the time of diagnosis. Results: We included 578 children (330 boys and 248 girls). The mean daily dose of GH in this study was 0.051 mg/kg, which was lower than the approved dose in Korea of 0.062 - 0.067 mg/kg. Height SDS was higher in patients who started treatment before the age of 6 years. The probability of reaching the target SDS (-1 SDS) from the beginning of treatment to 2-3 years after its start was higher in children starting treatment before the age of 6 years. The hazard ratio to reach the target SDS (-1 SDS) when using automatic pen or electronic devices was 1.727 times higher than that when using the needle and syringe device. Conclusion: ISS patients should start GH treatment at an early age, and even lower-than-recommended drug doses may be effective. The selection of automatic pen or electronic device can have a positive effect on reaching the target height SDS.
Asunto(s)
Trastornos del Crecimiento , Hormona de Crecimiento Humana , Estatura , Niño , Femenino , Trastornos del Crecimiento/tratamiento farmacológico , Hormona del Crecimiento/farmacología , Humanos , Masculino , Estudios RetrospectivosRESUMEN
In this work, three-armed luminogens IAcTr-out and IAcTr-in were synthesized and used as emitters bearing triazine and indenoacridine moieties in thermally activated delayed fluorescence organic light-emitting diodes (OLEDs). These molecules could form a uniform thin film via the solution process and also allowed the subsequent deposition of an electron transporting layer either by vacuum deposition or by an all-solution coating method. Intriguingly, the new luminogens displayed aggregation-induced emission (AIE), which is a unique photophysical phenomenon. As a nondoped emitting layer (EML), IAcTr-in showed external quantum efficiencies (EQEs) of 11.8% for the hybrid-solution processed OLED and 10.9% for the all-solution processed OLED with a low efficiency roll-off. This was evident by the higher photoluminescence quantum yield and higher rate constant of reverse intersystem crossing of IAcTr-in, as compared to IAcTr-out. These AIE luminogens were used as dopants and mixed with the well-known host material 1,3-bis( N-carbazolyl)benzene (mCP) to produce a high-efficiency OLED with a two-component EML. The maximum EQE of 17.5% was obtained when using EML with IAcTr-out doping (25 wt %) into mCP, and the OLED with EML bearing IAcTr-in and mCP showed a higher maximum EQE of 18.4% as in the case of the nondoped EML-based device.
RESUMEN
Two bipolar host materials, 8-(9H-carbazol-9-yl)-5-(pyridin-2-yl)-5H-pyrido[3,2-b]indole (CzCbPy) and 5-(6-(9H-carbazol-9-yl)pyridin-2-yl)-8-(9H-carbazol-9-yl)-5H-pyrido[3,2-b]indole (2CzCbPy), were synthesized for deep blue thermally activated delayed fluorescence organic light emitting diodes (TADF OLEDs). Both CzCbPy and 2CzCbPy hosts possess bipolar characteristic with high polarity, which results in high delayed photoluminescence quantum yields by reducing the energy gap between singlet and triplet states of TADF materials. In addition, these hosts have high enough triplet energies of 3.05 eV to transfer exciton energy to a deep blue TADF emitter. A deep blue TADF OLED fabricated with a CzCbPy host exhibited high external quantum efficiency of 22.9% and low efficiency roll-off (19.2% at 1000 cd m-2).